Synergy of drug combinations in treating multidrug-resistant Pseudomonas aeruginosa

Australasian Medical Journal

Volumn 8, Issue 1, 2015, Pages 1-6

  Rizvi, Meher ^a   Ahmad, Junaid ^a   Khan, Fatima ^a   Shukla, Indu ^a   Malik, Abida ^a   Sami, Hiba ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

Chequerboard technique; Multidrug resistance; Synergy; Time kill assay

Indexed keywords

CEFOPERAZONE PLUS SULBACTAM; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATION; CONTROLLED STUDY; DISK DIFFUSION; DRUG POTENTIATION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; QUANTITATIVE ASSAY; TREATMENT OUTCOME;

EID: 84922203357     PISSN: None     EISSN: 18361935     Source Type: Journal    
DOI: 10.4066/AMJ.2015.2096     Document Type: Article

References (24)

1. Rassolini GM, Mantengoli E. Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. Clin Microbiol Infec. 2005 Jul;11Suppl4:17–32.
2. Lambert RJW, Joynson J, Forbes B.The relationships and susceptibilities of some industrial, laboratory and clinical isolates of Pseudomonas aeruginosa to some antibiotics and biocides. J Applied Microbiol. 2002;91(6):972–84. doi: 10.1046/j.1365-2672.2001.01460.x
3. Matsuo Y, Eda S, Gotoh N, Yoshihara E, Nakae T.MexZ-mediated regulation of mexXY multidrug efflux pump expression in Pseudomonas aeruginosa by binding on the mexZ-mexX intergenic DNA. FEMS Microbiol Letters. 2004;238:23–8. doi: 10.1111/j.1574-6968.2004.tb09732.x
4. Japoni A., Hayati M., Alborzi A., Farshad S., Abbasian SA., In vitro susceptibility of Pseudomonas aeruginosaisolated from a burn centre to silver sulfadiazine and silver nitrate in Shiraz, South of Iran. Iran J Med Sci. 2005;30(2):63–7.
5. Eliopoulos GM, Moellering RC. In: Baltimore LV editors. Antibiotics in laboratory medicine. 3rd ed. Edited by Lorian V, Baltimore, The Williams & Wilkins Co.1991;p. 432–92.
6. Cappelletty DM, Raybak MJ. Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1996;40:677–83.
7. Chadwick EG, Shulman ST, Yogev R. Correlation of antibiotic synergy in vitro and in vivo: use of an animal model of neutropenic gram-negative sepsis. J InfectDis.1986;154:670–5.
8. Dudley MN, Blaser J, Gilbert D, Mayer KH, Zinner SH. Combination therapy of ciprofloxacin plus azlocillin against Pseudomonas aeruginosa: effect of simultaneous versus staggered administration in an in vitro model of infection. J Infect Dis. 1991;164:499–506.
9. Clinical and Laboratory Standards Institute 2003. Performance standards for antimicrobial susceptibility testing: eighteenth informational supplement: Approved standards M100-S18. Baltimore, USA: Clinical and Laboratory Standards Institute; 2008.
10. Rizvi M, Fatima N, Rashid M, Usman A, Siddiqui S. Extended spectrum AmpC and metallo-beta-lactamases in Serratia and Citrobacter spp. in a disc approximation assay. J Infect Dev Ctries. 2009;3(4):285–94.
11. Collee JG, Fraser AG, Marmion BP, Simmons A. Mackey and McCartney practical Medical Microbiology. 14th ed. New Delhi, India: Elsevier; 2006. Tests for the identification of bacteria; p. 131–49.
12. Hayami H, Goto T, Kawahara M. Activities of B-lactams, fluoroquinolones, amikacin and fosfomycin alone and in combination against Pseudomonas Aeruginosa isolated from complicated urinary tract infections. J Infect Chemother.1999;5:130–8.
13. Morrison A J Jr, Wenzel RP. Epidemiology of infection due to Pseudomonas aeruginosa.Rev. Infect. Dis. 1984;6(Suppl. 3):627–42.
14. National Nosocomial Infection Surveillance System.Am J Infect Control.2004;32:470–85.
15. Carmeli Y, Troillet N, Eliopoulos G, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother. 1999Jun;43:1379–82.
16. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control. 1988Jun;16:128–40.
17. Carmeli Y, Troillet N, Karchmer AW, Samore MH. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med. 1999May24; 159(10):1127–32.
18. Padmakrishnan RA, Murugan T, Devi MPR. Studies on multidrug resistant Pseudomonas aeruginosa from pediatric population with special reference to extended spectrum beta lactamase. Ind J Sci Tech. 2009;2(11):11–13.
19. Hancock REW. The role of fundamental research and biotechnology in finding solutions to the global problem of antibiotic-resistance. Clin Infect Dis. 1997;24(1):148–50.
20. Flynn CM, Johnson DM, Jones RN. In vitro efficacy of levofloxacin alone or in combination tested against multi-resistant Pseudomonas aeruginosa strains. J Chemother. 1996;8:411–5.
21. Mayer I, Nagy E. Investigation of the synergic effects of aminoglycoside-fluoroquinolone and third-generation cephalosporin combinations against clinical isolates of Pseudomonas spp. J Antimicrobiol Chemother. 1999;43:651–7.
22. Gradelski E, Valera L, Bonner D, Fung-Tomc J. Comparative killing kinetics of the novel des-fluoro(6) quinolone BMS-284756, fluoroquinolones, vancomycin and beta-lactams Int J Antimicrob Agents. 2001;45:3220–2.
23. Pankey GA, Ashcraft DS. In vitro synergy of ciprofloxacin and gatifloxacin against ciprofloxacin-resistant Pseudomonas aeruginos. Antimicrob Agents Chemother. 2005;49:2959–64.
24. Sivagurunathan N, Krishnan S, Rao VK, Nagappa AN, Subrahmanyam VM, Vanathi BM. Synergy of gatifloxacin with cefoperazone and cefoperazone-sulbactam against resistant strains of Pseudomonas aeruginosa. J Med Microbiol. 2008;57:1514–7.